Cytotoxicity of OKT9 ScFv-Diphtheria Toxin Fusion Immunotoxin on Human Brain Tumor Cell Lines.
- Author:
Oon Ki BACK
1
;
Yeung Jin SONG
;
Hee Woo LEE
;
Na Hee PARK
;
Yoon Cheong KIM
;
Su Yeong SEO
;
Ki Uk KIM
Author Information
1. Brain Tumor Institute, College of Medicine, Dong-A University, Busan, Korea. kukim@mail.donga.ac.kr
- Publication Type:Original Article
- Keywords:
Immunotoxin;
Brain tumor;
Transferrin receptor
- MeSH:
Brain Neoplasms*;
Brain*;
Cell Line*;
Central Nervous System;
Diphtheria Toxin;
Flow Cytometry;
Glioblastoma;
Humans*;
Immunotoxins*;
Medulloblastoma;
Receptors, Transferrin
- From:Journal of Korean Neurosurgical Society
2004;36(1):59-65
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Immunotoxin therapy is a novel approach for the treatment of tumor, and it has been successfully used in the central nervous system. The purpose of this study is to evaluate the cytotoxicity of OKT9 ScFv-Diphtheria toxin fusion immunotoxin on various human brain tumor cell lines. METHODS: Immunotoxin which was composed of OKT9 ScFv and Diphtheria toxin was made. Its cytotoxicity on glioblastoma cell lines(U87MG, U118MG) and medulloblastoma cell line(TE671) was tested and compared with anti-cancer chemotherapeutic agents. And we also examined the relationship between its cytotoxicity and transferrin receptor expression. RESULTS: It showed most cytotoxicity on U87MG cell line and nearly no effect on U118MG cell line, moderate cytotoxicity on TE671 cell line in sixteen hours exposure experiment. In continuous exposure experiment, it showed moderate cytotoxicity on U118MG cell line, but showed strong cytotoxicity on other cell lines comparable or higher than anti-cancer chemotherapeutic agents. The relationship between its cytotoxicity and transferrin receptor expression was tested using flow cytometry, but no direct relationship could be found. CONCLUSION: Collectively, the result shows the cytotoxic effects of OKT9 ScFv-Diphtheria toxin fusion immunotoxin against various human brain tumor cell lines in continuous exposure experiment. Therefore, we suggest that this immunotoxin could be developed as a potential immunotherapeutic agent in the treatment of various human brain tumor clinically.
